Brought to you by 
BioLineRx gets second HCV candidate from GenoScience; this one co-discovered by RFS Pharma
05 Mar 2012
Executive Summary
Antiviral therapeutics developer GenoScience Pharma and RFS Pharma LLC (developing treatments for HIV, hepatitis, and cancer) have licensed Israeli specialty pharma BioLineRx Ltd. exclusive global rights to a preclinical oral hepatitis C candidate, which BioLineRx has named BL8030.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioLineRx gets second HCV candidate from GenoScience; this one co-discovered by RFS Pharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice